Indiana University School of Medicine researcher Jeff Dage’s years of research into biomarkers helped lead to a ...

The FDA recently cleared the Lumipulse blood test for early diagnosis of Alzheimer's disease in ... More people 55 and over with memory loss. The noninvasive Lumipulse blood test measures the leve ...

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the ...

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary ...

GENT, Belgium & MALVERN, Pa. & TOKYO — H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated ...

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the ...

Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse ® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic ...

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only For media: Public Relations Section, Public Relations ...

United States: H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay ...

TOKYO, June 04, 2025--(BUSINESS WIRE)--H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated ...

Ixico said it was contracted by Fujirebio Diagnostics Inc, a Tokyo-based biomarker research company, to assist with the development of a new blood-based test for Alzheimer's disease called Lumipulse.

In patients showing cognitive decline, a new blood test for Alzheimer's is expected to make diagnosis more convenient, ...